

4 August 2025

Scancell Holdings plc
("Scancell" or the "Company")

Director Dealing

Scancell Holdings plc (AIM: SCLP), the developer of Immunobody® and Moditope® active immunotherapies to treat cancer, announces that Vulpes Testudo Fund, a fund closely associated with Martin Diggle, Non-Executive Director, has purchased 9,400,000 ordinary shares of 0.1p each ('Ordinary Shares') in the Company between 30 July 2025 and 1 August 2025 at a price of 10 pence per share. Following the purchase, Vulpes Life Science Fund and Vulpes Testudo Fund together hold 140,284,801 ordinary shares representing 13.52% of the company.

**NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM**

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name	Vulpes Testudo Fund
2	Reason for the notification	
a)	Position/status	Fund closely associated with Martin Diggle, Non-Executive Director
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Scancell Holdings plc
b)	LEI	2138008RXEG856SNP666
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 0.1 pence each
b)	Identification Code	GB00B63D3314
c)	Nature of the transaction	Purchase of Ordinary Shares
d)	Price(s) and volume(s)	1. 10 pence and 5,000,000 2. 10 pence and 4,400,000
e)	Aggregated information - Aggregated volume - Price	9,400,000 Ordinary Shares 10 pence per Ordinary Share
f)	Date of the transaction (s)	1. 30 July 2025 2. 1 August 2025
g)	Place of the transaction	London Stock Exchange, AIM

-ENDS-

Scancell (LSE:SCLP; www.scancell.co.uk) is a clinical stage biotechnology company developing targeted off-the-shelf active immunotherapies, to generate safe and long-lasting tumor-specific immunity for a cancer-free future. iSCIB1/iSCIB1+, the lead product from their DNA Immunobody® platform has demonstrated safe, durable and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the lead peptide immunotherapy from their Moditope® platform, is being investigated in a Phase 2 study in a broad range of solid tumors. In addition, Scancell's wholly-owned subsidiary, Glymab Therapeutics Ltd., is developing an exciting early-stage pipeline of high affinity GlyMab® antibodies targeting tumor specific glycans, two of which already have been licensed and are being developed by Genmab A/S, an international biotechnology company and global leader in the antibody therapeutics space.

For more information please contact:

Scancell Holdings plc

Phil L'Huillier, CEO

Sath Nirmalananthan, CFO

+44 (0) 20 3709 5700

Panmure Liberum (Nominated Adviser and Joint Broker)

Emma Earl, Will Goode, Mark Rogers (Corporate Finance)

Rupert Dearden (Corporate Broking)

+44 (0) 20 7886 2500

WG Partners LLP (Joint Broker)

David Wilson, Claes Spang

+44 (0) 20 3705 9330

Investor and media relations

Mary-Ann Chang

+44 (0) 20 7483 284853

MaryAnnChang@scancell.co.uk